A liquid biopsy is a minimally invasive alternative to a more traditional surgical solid tumor biopsy.
In this episode, Dr. Stephanie Hastings, genomics product lead at Q Squared Solutions, lays out the considerations for liquid biopsy collection and the type of information that can be gathered from circulating free DNA (cfDNA).
The main approaches comprise for evaluating cfDNA are:
- specific mutation detection to help support targeted therapies
- broader sequencing technologies to enable biomarker evaluations
- custom sequencing panels to support clinical trial assay development
She describes the typical panels for each of the approaches, the sample collection requirements and how these analyses are implemented on a global scale.
Podcasten Laboratory Considerations for Clinical Trials är inbäddad på denna sida från ett öppet RSS-flöde. Alla filer, beskrivningar, bilder och annan metadata från flödet tillhör podcastens ägare och är inte anslutet till eller validerat av Podplay.